SCYNEXIS (SCYX) 10-Q 13 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'SCYNEXIS Inc	'
Entity Central Index Key	'0001178253	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	8,502,055

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$38,425	$1,402
Accounts receivable, net of allowance for bad debts	965	719
Unbilled services	566	343
Prepaid expenses and other current assets	846	489
Total current assets	40,802	2,953
Property and equipment, net of accumulated depreciation	5,049	5,401
Deferred financing costs	0	2,144
Other assets	108	114
Deferred offering costs	0	1,775
Total assets	45,959	12,387
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Accounts payable	646	1,932
Accrued expenses	2,514	1,058
Deferred revenue, current portion	621	487
Current portion of long-term debt	0	15,000
Total current liabilities	3,781	18,477
Deferred revenue, net of current portion	1,330	1,144
Derivative liability	0	12,237
Deferred rent	1,425	1,481
Total liabilities	6,536	33,339
Commitments and contingencies (Note 5)	'	'
Stockholders' deficit:	'	'
Common stock, $0.001 par value, authorized 125,000,000 and 70,000,000 shares as of June 30, 2014, and December 31, 2013; 8,502,055 and 334,068 shares issued and outstanding as of June 30, 2014, and December 31, 2013	8	0
Additional paid-in capital	150,047	5,168
Accumulated deficit	-110,632	-113,277
Total stockholders' equity (deficit)	39,423	-108,109
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)	45,959	12,387
Series A Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	0	250
Series B Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	0	4,215
Series C Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	0	28,121
Series C-2 Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	0	13,500
Series D-1 Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	0	16,952
Series D-2 Convertible Preferred Stock [Member]	'	'
Liabilities, convertible preferred stock, and stockholders' equity (deficit)	'	'
Convertible preferred stock	$0	$24,119

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Dec. 31, 2000

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Dec. 31, 2000

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Dec. 31, 2002

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Mar. 31, 2008

Jun. 30, 2014

7-May-14

Dec. 31, 2013

Jun. 30, 2014

7-May-14

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Preferred stock, par value

'

'

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

'

$0.00

$0.00

'

'

$0.00

'

Preferred stock, shares authorized

'

29,135,824

'

0

31,410

31,410

'

0

711,987

711,987

'

0

2,967,678

2,967,678

'

0

2,347,826

2,347,826

'

0

10,000,000

10,000,000

0

10,000,000

'

10,000,000

'

Preferred stock, shares issued

'

'

'

0

'

31,407

31,407

0

'

467,814

600,999

0

'

2,770,633

2,867,154

0

'

2,347,826

2,347,826

0

'

6,054,255

0

'

388,641

5,742,697

1,785,712

Preferred stock, shares outstanding

'

'

'

0

'

31,407

'

0

'

467,814

'

0

'

2,770,633

'

0

'

2,347,826

'

0

'

6,054,255

0

'

'

5,742,697

'

Common stock, par value

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

125,000,000

'

70,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

8,502,055

'

334,068

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

8,502,055

'

334,068

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue - related party	$1,822	$1,822	$3,644	$3,644
Revenue	2,820	2,404	5,703	5,377
Total revenue	4,642	4,226	9,347	9,021
Cost of revenue	4,180	4,397	8,140	8,545
Gross profit	462	-171	1,207	476
Operating expenses:	'	'	'	'
Research and development	1,823	999	3,143	2,153
Selling, general and administrative	2,255	918	3,461	2,009
Gain on insurance recovery	-165	0	-165	0
Gain on sale of asset	0	-472	0	-986
Total operating expenses	3,913	1,445	6,439	3,176
Loss from operations	-3,451	-1,616	-5,232	-2,700
Other (income) expense:	'	'	'	'
Amortization of deferred financing costs and debt discount	219	813	755	1,522
Loss on extinguishment of debt	1,389	0	1,389	0
Interest expense - related party	0	228	0	454
Interest expense	5	46	49	96
Derivative fair value adjustment	-7,297	0	-10,080	0
Other expense	0	0	10	0
Total other (income) expense:	-5,684	1,087	-7,877	2,072
Net income (loss)	2,233	-2,703	2,645	-4,772
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock	0	0	-909	0
Deemed dividend for antidilution adjustments to convertible preferred stock	0	0	-214	0
Accretion of convertible preferred stock	0	0	-510	0
Allocation of net income to convertible preferred stockholders	-262	0	-303	0
Net income (loss) attributable to common stockholders	$1,971	($2,703)	$709	($4,772)
Per share information:	'	'	'	'
Net income (loss) per common share, basic	$0.38	($8.05)	$0.26	($14.21)
Net loss per common share, diluted	($0.98)	($8.05)	($3.08)	($14.21)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$2,645	($4,772)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Gain on insurance recovery	-165	0
Gain on sale of asset, net of transaction expenses	0	-986
Loss on extinguishment of debt	1,389	0
Recovery of bad debt	-75	-10
Depreciation	615	691
Stock-based compensation expense	382	83
Amortization of deferred financing costs and debt discount	755	1,522
Change in fair value of derivative liability	-10,080	0
Changes in deferred rent	-56	-22
Changes in operating assets and liabilities:	'	'
Accounts receivable and unbilled services	-394	181
Prepaid expenses, other assets, and deferred costs	-351	52
Accounts payable and accrued expenses	946	-307
Interest payable - related party	0	455
Deferred revenue	321	280
Net cash used in operating activities	-4,068	-2,833
Cash flows from investing activities:	'	'
Proceeds from insurance recovery	216	0
Proceeds from sale of asset, net of transaction expenses	0	986
Purchases of property and equipment	-323	-313
Net cash (used in) provided by investing activities	-107	673
Cash flows from financing activities:	'	'
Proceeds from initial public offering	62,000	0
Proceeds from issuance of convertible notes	0	632
Proceeds from sale of preferred stock	544	0
Repayment of debt	-15,000	0
Payments of deferred offering costs and underwriting discounts and commissions	-6,410	0
Proceeds from exercise of stock warrants	55	0
Proceeds from exercise of stock options	9	3
Net cash provided by financing activities	41,198	635
Increase (decrease) in cash and cash equivalents	37,023	-1,525
Cash and cash equivalents, beginning of period	1,402	2,385
Cash and cash equivalents, end of period	38,425	860
Supplemental cash flow information:	'	'
Cash paid for interest	49	97
Noncash financing and investing activities:	'	'
Beneficial conversion feature on sale of Series D-2 preferred stock	909	0
Beneficial conversion feature for antidilution adjustment	214	0
Adjustment of preferred stock to redemption value	510	0
Deemed contribution of a loan guarantee	0	3,930
Deferred offering costs included in accounts payable and accrued expenses	465	0
Equipment purchase in accounts payable and accrued expenses	6	9
Impairment of fixed asset	51	0
Deferred offering costs reclassified to additional paid-in capital	4,127	0
Warrant derivative liability reclassified to additional paid-in capital	2,701	0
Conversion of convertible preferred stock to common stock	88,790	0
Other receivable due from holders of June 2013 convertible notes	$0	$267

Description_of_Business_and_Ba

Description of Business and Basis of Preparation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Description of Business and Basis of Preparation	'
	1	Description of Business and Basis of Preparation
	Organization
	SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a pharmaceutical company, headquartered in Research Triangle Park, North Carolina, committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. The Company also offers its services and partnerships in the drug discovery and development phases, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects.
	Reverse stock-split
	On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties.
	On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties.
	All disclosures of common shares and per common share data in the accompanying interim financial statements and related notes reflect these two reverse stock splits for all periods presented.
	Initial public offering
	On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock under the registration statement on Form S-1 declared effective by the Securities and Exchange Commission (“SEC”) on May 2, 2014, at a public offering price of $10.00 per share. Net proceeds were $54,583, after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127. Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000, plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. The significant increase in the shares outstanding in May 2014 is expected to impact the comparability of our net income (loss) per share calculations between 2013 and 2014 periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Unaudited Interim Financial Information
	The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six months ended June 30, 2014, are not necessarily indicative of the results for the full year or the results for any future periods. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s registration statement on Form S-1 under the Securities Act of 1933, as amended, filed with and declared effective by the SEC on May 2, 2014.
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; and the estimated useful lives of property and equipment.
	Concentration of Credit Risk
	Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with a bank which exceeds insured limits, and accounts receivable and unbilled services. The Company performs ongoing credit evaluations of customer’s financial condition and does not require collateral.
	Cash and Cash Equivalents
	The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.
	Accounts Receivable and Unbilled Services
	Accounts receivable and unbilled services consist of amounts billed and unbilled under the Company’s service contracts with its customers. The Company extends credit to customers without requiring collateral. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. The allowance for bad debts was $0 and $163 as of June 30, 2014, and December 31, 2013, respectively.
	Deferred Financing Costs
	Deferred financing costs are transaction costs associated with issuing debt as well as costs related to a deemed contribution for a guarantee from a related party. The Company recognizes these costs in the balance sheet as noncurrent assets. Deferred financing costs are amortized over the life of the related debt.
	Deferred Offering Costs
	Deferred offering costs are expenses directly related to the IPO. These costs consist of legal, accounting, printing, and filing fees that the Company capitalized, including fees incurred by the independent registered public accounting firm directly related to the offering. The deferred offering costs were offset against the IPO proceeds in May 2014 and were settled to additional paid-in capital.
	Revenue Recognition and Deferred Revenue
	The Company derives the majority of its revenue from providing contract research and development services under fee for service arrangements. The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales.
	Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured.
	When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements. If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting.
	An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered.
	The Company’s contract research and development services revenue is recognized in the period in which the services are performed. The Company historically has recognized milestone payments received on a straight-line basis over the remaining service period. No milestone payments were received in the periods presented in the accompanying statements of operations. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. Therefore, license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company recognized an immaterial amount of license revenue from the receipt of upfront payments in the accompanying statement of operations. The Company has not received any royalty payments to date.
	The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement.
	Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets.
	The Company’s deferred revenue comprises upfront payments received and is recognized over the estimated relationship period. The Company received upfront payments of $313, $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue from these upfront payments of $96 and $189 for the three and six months ended June 30, 2014, respectively, and $0 and $62 for the three and six months ended June 30, 2013, respectively.
	Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.
	The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:
		•	Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
		•	Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
		•	Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
	Research and Development
	Major components of research and development costs include cash compensation, stock-based compensation, preclinical studies, clinical trial and related clinical manufacturing, drug development, materials and supplies, legal, regulatory compliance, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf.
	Amortization of Deferred Financing Costs and Debt Discount
	Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (Note 4), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party.
	Comprehensive Income or Loss
	The Company has no items of comprehensive income or loss other than net income or loss.
	Income Taxes
	The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.
	Stock-Based Compensation
	The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service period.
	The Company also accounts for equity instruments issued to non-employees using a fair value approach. The Company values equity instruments and stock options granted to employees using the Black-Scholes valuation model. The measurement of non-employee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received. The Company estimates the fair value of common stock warrants granted to lenders at their intrinsic value, which is the estimated fair value of the common stock less the exercise price for the warrant.
	Basic and Diluted Earnings (Net Loss) per Share of Common Stock
	The Company uses the two-class method to compute earnings (net loss) per common share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the board of directors that were made to common stockholders, and as a result were considered participating securities.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	3	Property and Equipment
	Property and equipment consists of the following:
			June 30,		December 31,
			2014		2013
	Equipment		$	9,891	$	9,577
	Furniture and fixtures			378		378
	Leasehold improvements			13,115		13,115
	Total property and equipment			23,384		23,070
	Less accumulated depreciation			18,335		17,669
	Property and equipment, net		$	5,049	$	5,401
	Depreciation expense was $307 and $615 for the three and six months ended June 30, 2014, respectively, and $343 and $691 for the three and six months ended June 30, 2013, respectively.
	In the quarter ended June 30, 2014, the Company’s insurance carrier remitted proceeds for the replacement cost of a fixed asset that was damaged by severe weather. The asset’s net book value was reduced upon occurrence of the damage. The proceeds received from the insurance recovery exceeded the net book value of the asset by $165, which was recognized as a gain during the quarter ended June 30, 2014. The replacement asset has been ordered and is expected to be delivered, installed and placed in service during the quarterly period ended September 30, 2014.

Debt_Obligations

Debt Obligations	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Obligations	'
	4	Debt Obligations
	Credit Facility Agreement
	In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants. On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company.
	At the inception of the 2010 Credit Agreement, a deemed contribution in relation to the guarantee of the 2010 Credit Agreement was recognized as deferred financing costs and amortized over the life of the loan. The value of the guarantee was determined based on the difference between the loan’s stated interest rate and the interest rate that would apply if there had been no guarantee from the related party. The Company determined the value of the 2010 Credit Agreement guarantee to be $6,338, which was amortized over the original life of the loan.
	The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930, which was amortized over the term of the 2013 Credit Agreement. The unamortized deferred financing costs of the deemed contribution related to the guarantee of the 2010 Credit Agreement amounting to $153 were expensed at the date of the amendment. As of December 31, 2013, both the $5,000 term loan and the $10,000 revolving credit facility were outstanding under the 2013 Credit Agreement.
	On March 17, 2014, the Company entered into an addendum to the guarantee agreement with the related party who guaranteed its 2013 Credit Agreement. Under this addendum, the Company agreed: (i) to use $7,500 of the proceeds from the Company’s planned IPO to repay a portion of the outstanding amounts under the 2013 Credit Agreement by June 30, 2014; (ii) to amend the 2013 Credit Agreement by June 30, 2014 to reduce the aggregate amount the Company may borrow to $7,500; and (iii) to repay all amounts owed under the 2013 Credit Agreement by December 31, 2014 in order to release the related party from its obligations under the guarantee.
	On April 29, 2014, the Company entered into another addendum to the agreement with the related party guarantor. Under this addendum and conditioned upon the closing of the IPO, the parties agreed to terminate the Company’s obligations made under the addendum dated March 17, 2014. Under this addendum, the Company agreed that to the extent the related party guarantor invested in the IPO, the amount invested by the related party guarantor would be used to pay down the outstanding balance under the 2013 Credit Facility.
	Upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014 as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of June 30, 2014.
	Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $219 and $755 for the three and six months ended June 30, 2014, respectively, and $534 and $1,243 for the three and six months ended June 30, 2013, respectively.
	The weighted-average interest rate was 1.19% for both the three and six months ended June 30, 2014, and 1.23% and 1.22% for the three and six month periods ended June 30, 2013, respectively. Interest expense was $5 and $49 for the three and six months ended June 30, 2014, respectively, and $46 and $96 for the three and six months ended June 30, 2013, respectively.
	Note and Warrant Purchase Agreements
	In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000. In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that hold investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement.
	In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899. In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using similar methods described in the 2011-2012 Notes. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders.
	The 2011-2012 Notes and June 2013 Notes carried interest at a rate of 8% per annum and contained no financial covenants. The outstanding principal amount and unpaid accrued interest on the convertible notes issued under the December 2011 Note and Warrant Agreement and the June 2013 Note and Warrant Agreement were originally due on December 31, 2012 and December 31, 2013, respectively, contingent upon (i) the prior written consent of holders of at least 70% of the outstanding aggregated principal amount of the convertible notes issued under the same agreement, and (ii) the prior written consent of HSBC Bank for so long as any of the principal and interest related to the 2010 Credit Agreement or the 2013 Credit Agreement remained outstanding.
	On the date of issuance, the fair value of warrants issued in the year ended December 31, 2012 under the December 2011 Note and Warrant Agreement was $328. The fair value of these warrants was accounted for as debt discount and amortized to expense over the stated term of the 2011-2012 Notes. The fair value of the obligation to issue warrants in connection with the June 2013 Notes was $1,168. The fair value of the obligation to issue warrants was $269 above the face value of the June 2013 Notes and this excess was expensed at issuance. The $899 remaining amount of the fair value of the obligation to issue warrants was accounted for as a debt discount and was amortized to expense over the term of the June 2013 Notes. The amount of the discount related to the 2011-2012 Notes’ warrants and the June 2013 Notes’ obligation to issue warrants that was amortized to expense was $0 for both the three and six month periods ended June 30, 2014, and $10 for both the three and six month periods ended June 30, 2013.
	On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Under the election, the outstanding principal and accrued interest balance of $899 and $33, respectively, was converted into 665,542 shares of Series D-2 convertible preferred stock at a conversion price of $1.40 per share. Consistent with the original terms of the June 2013 Notes, the conversion price was adjusted to $1.40 per share because the Company adjusted the conversion price of the 2011-2012 Notes in connection with the sale and issuance of shares of Series D-2 convertible preferred stock on December 11, 2013 (Note 6).
	Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. Under the election, the outstanding principal and accrued interest balance of $11,444 and $1,640, respectively, was converted into 6,054,255 shares of Series D-1 convertible preferred stock and 3,291,443 shares of Series D-2 preferred stock at a conversion price of $1.40 per share. The conversion price of the 2011-2012 Notes was adjusted to $1.40 per share in connection with the sale and issuance of shares of Series D-2 convertible preferred stock on December 11, 2013 (Note 6).

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	5	Commitments and Contingencies
	Leases
	The Company leases its facilities and certain office equipment under long-term non-cancelable operating leases. The Company’s lease for its primary North Carolina facility expires in 2019. The lease agreement includes a renewal option to extend the lease through March 31, 2024.
	Rent expense was approximately $236 and $467 for the three and six months ended June 30, 2014, respectively, and $227 and $450 for the three and six months ended June 30, 2013, respectively. Future minimum lease payments for all operating leases as of June 30, 2014 are as follows:
	2014		$	530
	2015			1,075
	2016			1,104
	2017			1,123
	2018			1,156
	Thereafter			291
	Total		$	5,279
	License Arrangement with Potential Future Expenditures
	As of June 30, 2014, the Company had a license arrangement with Merck that involves potential future expenditures. Under the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon initiation of SCY-078, the Company’s lead product candidate, phase 2 and 3 clinical studies, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits. The Company has two additional licensing agreements that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company.
	Clinical Development Arrangement
	In June 2014, the Company entered into an agreement with a third-party clinical research organization to conduct a Phase 2 clinical trial for SCY-078. The total fees and expenses under the agreement are projected to be approximately $6.2 million during the term of the agreement. The Company had no such commitments as of December 31, 2013. The scope of the services under the agreement can be modified at any time, and the agreement can be terminated by either party 30 days after receipt of written notice.

Convertible_Preferred_Stock

Convertible Preferred Stock

6 Months Ended

Jun. 30, 2014

Text Block [Abstract]

'

Convertible Preferred Stock

'

6

Convertible Preferred Stock

Convertible preferred stock had a par value of $0.001 and was issued beginning in 2000. Each issuance is briefly described as follows:

Series A Convertible Preferred Stock (“Series A Preferred”)

In 2000, the Company issued 31,407 shares of Series A Preferred at $7.96 per share to its initial employees and consultants.

Series B Convertible Preferred Stock (“Series B Preferred”)

In 2000, the Company issued 600,999 shares of Series B Preferred at $9.01 per share in exchange for $2,200 in equipment, intellectual property, and conversion of existing debt, and $3,215 in cash, and incurred issuance costs of $43. Subsequently in 2000, the Company issued an additional 110,988 shares of Series B Preferred at $9.01 per share for cash. As part of the issuance of the Series C convertible preferred stock in June 2002, the holders of Series B Preferred agreed to modify the redemption feature of the Series B Preferred to eliminate this feature. As described below, 244,173 shares of Series B Preferred were mandatorily converted into common stock during 2012.

Series C Convertible Preferred Stock (“Series C Preferred”) and Warrants

The Company issued warrants to purchase 100,524 shares of Series C Preferred in conjunction with certain bridge loan financings during 2001 and the subsequent 2002 Series C Preferred financing. The warrants were issued with an exercise price of $0.01 per share. Two of the investors exercised such warrants during 2003.

In 2002, the Company issued 2,867,154 shares of Series C Preferred for $24,000 in cash and the conversion of approximately $4,513 of 4.5% convertible notes and accrued interest, less issuance costs of approximately $86. As described below, 197,045 shares of Series C Preferred were mandatorily converted into common stock during 2012. In January 2005, the remaining warrants to purchase 23,911 shares of Series C Preferred shares were exercised.

Series C-1 Convertible Preferred Stock (“Series C-1 Preferred”) and Warrants

In August 2004, the Company received cash of $3,200 for the issuance of 984,615 shares of Series C-1 Preferred. As described below, these Series C-1 Preferred shares were mandatorily converted into common stock during 2012.

In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Preferred in conjunction with a loan financing agreement. The warrants were issued with an exercise price of $3.25 per share and will expire on July 14, 2016. The fair value at the date of grant for these instruments was $459, which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $0 and $37 for the three and six month periods ended June 30, 2014, respectively, and $0 for both the three and six month periods ended June 30, 2013, respectively.

Series C-2 Convertible Preferred Stock (“Series C-2 Preferred”)

In March 2008, the Company received cash of $13,500 for the issuance of 2,347,826 shares of Series C-2 Preferred.

Series D-1 Convertible Preferred Stock (“Series D-1 Preferred) and Series D-2 Convertible Preferred Stock (“Series D-2 Preferred”)

On December 11, 2013, the Company entered into an agreement to sell 1,785,712 shares of Series D-2 Preferred at $1.40 per share for an aggregate price of $2,500 (the “Series D-2 Purchase Agreement”), less issuance costs of $95. With the sale of the Series D-2 Preferred on December 11, 2013 at a price of $1.40 per share, the antidilution provisions associated with the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were triggered. As of December 11, 2013, the conversion price of the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were reduced from $45.95, $51.77, $66.30, and $117.30, respectively, to $32.2912, $36.2386, $46.1101, and $78.9623, respectively.

The Series D-2 Purchase Agreement also included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214, which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. The Company calculated the fair value of the warrants as the difference between the estimated fair value of the common stock on December 11, 2013 of $48.35 per share and the exercise price per share of $0.20 multiplied by the number of shares of common stock issuable upon exercise of the warrants of 87,532. The Company determined that the warrants should be classified as a derivative liability and stated at fair value at each reporting period.

The Series D-2 Preferred was convertible into shares of common stock at a conversion price of $28.56 per share. Since the fair value of the common stock on December 11, 2013 was $48.35, the Company determined that the sale of the Series D-2 Preferred resulted in a beneficial conversion feature. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the common stock on December 11, 2013 of $48.35 per share and the effective conversion price per share of $0 multiplied by the number of shares of common stock issuable upon exercise of the warrants of 87,352. The intrinsic value was calculated at $4,232, which the Company recorded as a reduction to additional paid-in capital.

Concurrent with the sale of the Series D-2 Preferred, the Company modified the terms of the 2011-2012 Notes and the related warrants and the June 2013 Notes and related warrants (Note 4). Under the amendments, the outstanding principal and accrued interest balance was converted into Series D-1 Preferred and Series D-2 Preferred at a conversion price of $1.40 per share. As a result of the conversions, the Company issued 6,054,255 shares of Series D-1 Preferred and 3,956,985 shares of Series D-2 Preferred.

On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544. The sale also included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906. The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. The Company calculated the fair value of the warrants as the difference between the estimated fair value of the common stock on January 31, 2014 of $47.74 per share and the exercise price per share of $0.20 per share multiplied by the number of shares of common stock issuable upon exercise of the warrants of 19,048. The warrants are classified as a derivative liability and stated at fair value at each reporting period. With the sale of the Series D-2 Preferred on January 31, 2014 at a price of $1.40 per share, the antidilution provisions associated with the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were triggered. As of January 31, 2014, the conversion price of the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were reduced from $32.2912, $36.2386, $46.1101, and $78.9623, respectively, to $32.0076, $35.8917, $45.6062, and $77.9382, respectively.

Automatic Conversion of Preferred Stock

On March 13, 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of the convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000. There were no other changes in significant terms of the convertible preferred stock during the six months ended June 30, 2014. In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their conversion prices.

Authorized, Issued, and Outstanding Preferred Shares

The following table summarizes authorized, issued and outstanding preferred shares as of May 7, 2014, immediately prior to the automatic conversion to shares of common stock:

Authorized

Issued and

Outstanding

Series A Preferred

31,410

31,407

Series B Preferred

711,987

467,814

Series C Preferred

2,967,678

2,770,633

Series C-1 Preferred

3,076,923

—

Series C-2 Preferred

2,347,826

2,347,826

Series D-1 Preferred

10,000,000

6,054,255

Series D-2 Preferred

10,000,000

6,131,338

Total

29,135,824

17,803,273

Preferred Stock Activity

The following table summarizes preferred stock activity for the six months ended June 30, 2014:

Shares of

Series A

Series B

Series C

Series C-1

Series C-2

Series D-1

Series D-2

Convertible

Convertible

Convertible

Convertible

Convertible

Convertible

Convertible

Preferred

Preferred

Preferred

Preferred

Preferred

Preferred

Preferred

Stock

Stock

Stock

Stock

Stock

Stock

Stock

Balance, December 31, 2013

31,407

467,814

2,770,633

—

2,347,826

6,054,255

5,742,697

Issuance of Series D-2 Preferred

—

—

—

—

—

—

388,641

Automatic conversion to common stock

(31,407

)

(467,814

)

(2,770,633

)

—

(2,347,826

)

(6,054,255

)

(6,131,338

)

Balance, June 30, 2014

—

—

—

—

—

—

—

Common_Stock

Common Stock	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Common Stock	'
	7	Common Stock
	Authorized, Issued, and Outstanding Common Shares
	The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares and 70,000,000 authorized shares at June 30, 2014, and December 31, 2013, respectively; 8,502,055 and 334,068 shares were issued and outstanding at June 30, 2014, and December 31, 2013, respectively. The following table summarizes common stock share activity for the six months ended June 30, 2014:
			Shares of
			Common Stock
	Balance, December 31, 2013			334,068
	Exercise of stock options			416
	Conversion of preferred stock			1,691,884
	Exercise of common stock warrants			275,687
	Common stock issued through IPO			6,200,000
	Balance, June 30, 2014			8,502,055
	Shares Reserved for Future Issuance
	The Company had reserved shares of common stock for future issuance as follows:
			As of		As of
			June 30,		December 31,
			2014		2013
	For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased			—		1,675,812
	Outstanding stock options *			215,467		137,610
	Outstanding common stock warrants			—		257,242
	For possible future issuance under stock option plan *			228,812		49,734
	For possible future issuance under employee stock purchase plan			47,794		—
	Total common shares reserved for future issuance			492,073		2,120,398
	*	Excludes the effects of the 2014 Equity Incentive Plan amendment and option grants described in Note 8, which were approved by the Board of Directors on June 18, 2014 but are contingent upon approval by the Company’s stockholders.
	Warrants issued from the Note and Warrant Purchase Agreements
	The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements the Company executed in December 2011 and June 2013 (Note 4).
	The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms, at the earliest of:
		(i)	The date the related convertible notes were converted,
		(ii)	The date the related convertible notes were repaid or prepaid in full, and
		(iii)	June 30, 2012.
	These warrants would expire on June 30, 2017, and would terminate unless exercised prior to an IPO. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (Note 4).
	On December 11, 2013, holders of the June 2013 Notes, under the June 2013 Note and Warrant Agreement, exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018, and would terminate unless exercised prior to an IPO.
	On December 11, 2013, in connection with the Series D-2 Purchase Agreement (Note 6), the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (Note 6), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120.
	In connection with the consummation of the IPO in May 2014, substantially all outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock.
	These warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date. The combined fair value of the common stock warrant derivative liabilities was $12,200 as of December 31, 2013, which was recorded as a long-term derivative liability in the accompanying balance sheet. The fair value adjustment of the long-term derivative liability was recorded as other income in the amounts of $7,297 and $10,442 for the three and six months ended June 30, 2014, respectively, and other income/loss of $0 for both the three and six months ended June 30, 2013, respectively. As discussed in Note 6, the fair value of the warrants issued in connection with the Company’s Series D-2 Preferred offering in January 2014 was $362 above the face amount of the Series D-2 Preferred. This excess was expensed in the six months ended June 30, 2014, and, as a result, the net fair value adjustment presented in the accompanying statements of operations for the six months ended June 30, 2014 is $10,080.

Stockbased_Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-based Compensation	'
	8	Stock-based Compensation
	2009 Stock Option Plan
	The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.
	2014 Equity Incentive Plan
	In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards.
	Under the 2014 Plan, the aggregate number of shares of common stock that may be issued from and after the Effective Date (the “share reserve”) will not exceed the sum of 257,352 new shares, the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and any returning shares from the 2009 Stock Option Plan. The share reserve will automatically increase on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The Board of Directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur.
	On June 18, 2014, the Company’s Board of Directors and Compensation Committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan otherwise remain unchanged. The Company’s stockholders had not received the 2014 Plan amendment for vote, nor had the amendment been approved by the stockholders, as of June 30, 2014.
	Also on June 18, 2014, the Company’s Board of Directors approved, contingent upon stockholder approval of the additional 351,653 shares to be added to the share reserve under the 2014 Plan, the grant of options to purchase 396,573 shares of common stock at a per share exercise price of $9.64 to certain of the Company’s executive officers and employees. The Company does not believe stockholder approval of the share reserve amendment is perfunctory. No compensation cost was recognized during the period ending June 30, 2014 associated with previously described option grants because they are subject to and contingent upon approval by the Company’s stockholders.
	As of June 30, 2014, there were 228,812 shares of common stock available for future issuance under the 2014 Plan, which excludes the effects of the previously described 2014 Plan amendment and option grants that were approved by the Board of Directors on June 18, 2014, but are contingent on approval by the Company’s stockholders.
	Option Amendments
	During the quarter ended June 30, 2014, the Board of Directors of the Company approved the following with respect to the 2009 Stock Option Plan:
		•		On April 29, 2014, the exercise price per share of certain options to purchase 53,404 shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $10.00 per share, the initial public offering price per share in the IPO. The original exercise prices of such options ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $54.87 per share.
		•		On June 18, 2014, the exercise price per share of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $9.64 per share, the closing stock price on June 18, 2014. This modification lowered the exercise price of outstanding options to purchase 110,346 shares of common stock, including those options to purchase common stock that were previously modified on April 29, 2014. These outstanding stock options had exercise prices that ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $41.87 per share.
		•		Also on June 18, 2014, the contractual term of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was extended to June 17, 2024.
	The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation. The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model, consistent with and in accordance with the Company’s existing accounting policy for stock compensation (Note 1). Using the Black-Scholes option-pricing model, the weighted-average fair value of outstanding 2009 Stock Option Plan option awards was $3.08 per option immediately prior to modification on June 18, 2014 and was $5.87 per option immediately after modification. The additional compensation cost was determined to be $293, of which $130 was associated with services previously performed and, therefore, was expensed in the quarter ending June 30, 2014. The remaining additional compensation cost is associated with future service periods and will be recognized as those services are performed.
	Also on June 18, 2014, the Board of Directors approved modifications to the exercise price and contractual term of all outstanding option awards under the Company’s Stock Option Plan previously adopted by the Company in 1999 (the “1999 Stock Option Plan”). The modifications to the exercise price and contractual term are consistent with those previously described for outstanding options under the 2009 Stock Option Plan. In addition, the 1999 Stock Option Plan option awards were modified to provide that the holder may exercise vested shares under the option for the contractual term of the option even in the event the holder terminates services with the Company other than for cause. Pursuant to the terms of the 1999 Stock Option Plan, any amendments that modify the terms of the options awards require approval or consent of the Company’s shareholders. The Company’s stockholders had not received the 1999 Stock Option Plan amendment for vote, nor had the amendments been approved by the stockholders as of June 30, 2014. The Company does not believe stockholder approval of the amendments is perfunctory. Therefore, no additional compensation cost was recognized during the period ended June 30, 2014, associated with the modifications to the 1999 Stock Option Plan option awards.
	2014 Employee Stock Purchase Plan
	In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the ESPP is to provide means by which eligible employees and certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code.
	Compensation Cost
	The compensation cost that has been charged against income for stock awards under both the 2009 Stock Option Plan and the 2014 Plan was $272 and $382 for the three and six month periods ended June 30, 2014, respectively, and $42 and $83 for the three and six month periods ended June 30, 2013, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for the three and six months ended June 30, 2014 and 2013. Cash received from options exercised was $4 and $9 for the three and six months ended June 30, 2014, respectively, and $5 for the year ended December 31, 2013.
	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations:
			Three Months Ended June 30,				Six Months Ended June 30,
			2014		2013		2014		2013
	Cost of revenue		$	37	$	11	$	50	$	22
	Research and development			100		7		162		14
	Selling, general and administrative			135		24		170		47
			$	272	$	42	$	382	$	83

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9	Income Taxes
	The Company did not record a federal or state income tax benefit for the three and six months ended June 30, 2014 and 2013 due to its conclusion that a full valuation allowance is required against the Company’s deferred tax assets.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	10	Earnings Per Share
	The Company uses the two-class method to compute earnings per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company.
	Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income per share during the period.
	The following table summarizes the computation of basic and diluted net income (loss) per share attributable to the Company’s common stockholders:
			Three Months Ended						Six Months Ended
			2014			2013			2014			2013
	Net income (loss)		$	2,233		$	(2,703	)	$	2,645		$	(4,772	)
	Deemed dividend for beneficial conversion feature on Series D-2 Preferred			—			—			(909	)		—
	Deemed dividend for antidilution adjustments to convertible preferred stock			—			—			(214	)		—
	Accretion of convertible preferred stock			—			—			(510	)		—
	Allocation of net income to convertible preferred stockholders			(262	)		—			(303	)		—
	Net income (loss) attributable to common stock - basic		$	1,971		$	(2,703	)	$	709		$	(4,772	)
	Derivative fair value adjustment			(7,297	)		—			(10,080	)		—
	Net loss attributable to common stock - diluted		$	(5,326	)	$	(2,703	)	$	(9,371	)	$	(4,772	)
	Weighted-average common shares outstanding - basic			5,181,174			335,889			2,771,020			335,835
	Allocation of common stock warrants as participating securities			273,197			—			273,709			—
	Weighted-average of outstanding common stock - diluted			5,454,371			335,889			3,044,729			335,835
	Net income (loss) per share
	Basic		$	0.38		$	(8.05	)	$	0.26		$	(14.21	)
	Diluted		$	(0.98	)	$	(8.05	)	$	(3.08	)	$	(14.21	)
	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because the effect is anti-dilutive. The convertible preferred stock securities will no longer be potentially dilutive in future periods because, as discussed in Note 6, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices.
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Convertible preferred stock:
	Series A Preferred			6,149			6,149			6,149			6,149
	Series B Preferred			131,685			93,566			131,685			93,566
	Series C Preferred			783,515			554,174			783,515			554,174
	Series C-2 Preferred			173,213			119,958			173,213			119,958
	Series D-1 Preferred			296,773			—			296,773			—
	Series D-2 Preferred			300,549			—			300,549			—
	Warrants to purchase Series C-1 Preferred			14,033			9,846			14,033			9,846
	Warrants to purchase common stock			—			114,987			—			114,987
	Stock options			215,467			—			215,467			—
	Convertible notes			—			475,323			—			475,323

RelatedParty_Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	11	Related-Party Transactions
	The Company had transactions with related parties as follows:
			Three Months Ended June 30,				Six Months Ended June 30,
			2014		2013		2014		2013
	Revenue		$	1,822	$	1,822	$	3,644	$	3,644
	Selling, general and administrative expense			500		—		500		—
	Sanofi owns 100% of a subsidiary that is a customer of the Company. Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with the subsidiary composed 39% of total revenue for both the three and six months ended June 30, 2014, respectively, and composed 43% and 40% of total revenue for the three and six months ended June 30, 2013, respectively.
	In May 2013, the Company entered into an engagement letter with Burrill Securities, an affiliate of Burrill Biotechnology Capital Fund, L.P., a holder of the Company’s capital stock. Pursuant to the letter, Burrill Securities assisted the Company with the identification of certain strategic alternatives. Under the letter, the Company would have owed Burrill Securities a success fee of 5% of the transaction value of any strategic transaction or financing transaction resulting from the engagement and that closed during the term of the letter or within twelve months after the end of the term of the letter. The term of the letter expired on November 17, 2013. In December 2013, the Company entered into an amendment to the engagement letter that provided that notwithstanding anything to the contrary in the engagement letter, in the event the Company consummated a public offering of its common stock prior to November 17, 2014, the Company would pay Burrill Securities a success fee of $500 as payment in full for all its obligations under the engagement letter. In May 2014, the Company paid the $500 success fee to Burrill Securities pursuant to the engagement letter, as amended, and the fee was recognized as general and administrative expense in the accompanying statements of operations.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	12	Fair Value Measurements
	The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made.
	As of June 30, 2014, there were no assets or liabilities measured at fair value on a recurring basis.
	The following table summarizes the conclusions reached as of December 31, 2013:
			Balance as of			Quoted Prices in		Significant Other		Significant
			December 31, 2013			Active Markets for		Observable Inputs		Unobservable
						Identical Assets		(Level 2)		Inputs
						(Level 1)				(Level 3)
	Derivative liability — Series C-1 warrants		$	37		$	—	$	—	$	37
	Derivative liability — common stock warrants			12,200			—		—		12,200
	Total derivative liability		$	12,237		$	—	$	—	$	12,237
	The Company’s derivative liabilities were the only balance sheet amounts that were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario.
	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:
			Six months ended
			June 30, 2014
	Beginning balance, December 31, 2013		$	12,237
	Issuance of warrants			544
	Excess of fair value of warrants over proceeds			362
	Adjustment to fair value			(10,442	)
	Reclassification to additional paid-in capital upon exercise of warrants			(2,701	)
	Ending balance, June 30, 2014		$	—

Significant_Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Significant Agreements	'
	13	Significant Agreements
	In August 2013, the Company entered into a development, license, and supply agreement with R-Pharm, CJSC or R-Pharm, granting it exclusive rights to develop and commercialize an anti-fungal drug (SCY-078) in the field of human health in Russia and certain smaller non-core markets. The Company received an upfront payment of $1,500, and is entitled to receive payments on contingent events, including 1) a development milestone payment of $3,000 upon the first registration of SCY-078 in any country covered by the agreement; 2) sales-based payments of up to $15,000 upon R-Pharm’s achievement of specified targets for cumulative net sales of SCY-078; and 3) percentage royalties of up to the mid-teens on SCY-078 net sales.
	The Company deferred the upfront payment received and is recognizing it over the estimated relationship period of 70 months, which includes the product development period and an additional period during which the Company is required to participate in a product development committee. The development milestone payment is considered substantive and will be recognized when R-Pharm achieves certain specified milestones.
	The sales-based payments will not be recognized until the Company 1) receives the payments, and 2) has no continuing performance obligations. If the Company has any continuing performance obligations when the sales-based payments are received, those payments will be deferred and recognized over the remaining period of continuing performance obligations. Royalties will be recognized when payment is received.
	In December 2013, the Company entered into a licensing agreement with Elanco Animal Health (“Elanco”). The agreement includes an upfront payment of $500 and multi-year contract research and development services with fees of $2,750 annually for the first two years and $3,000 annually for the second two years, and entitles the Company to: 1) development milestone payments of up to $1,500 for each compound Elanco and the Company decide to develop; 2) a one-time payment of up to $2,000 for the first regulatory approval of any product in the U.S.; 3) a one-time payment of $4,000 for the first commercial sale of a product in the U.S. and a one-time payment of $1,500 for the first commercial sale of a product in the European Union; 4) one-time payments of up to $15,000 for reaching specified annual sales of a product; and 5) mid-single-digit percentage royalties on net annual sales. The Company has deferred the upfront payment, which it received in January 2014, and is recognizing the revenue over the research and development period of 48 months.

Severance_Costs

Severance Costs	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Severance Costs	'
	14	Severance Costs
	In June 2014, the Company reduced its workforce in an effort to reduce operating costs. Employee severance costs associated with this action were $379 for the three and six months ended June 30, 2014. The severance costs were unpaid as of June 30, 2014, and, therefore, are included in accrued expenses in the accompanying balance sheets.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Unaudited Interim Financial Information	'
	Unaudited Interim Financial Information
	The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six months ended June 30, 2014, are not necessarily indicative of the results for the full year or the results for any future periods. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s registration statement on Form S-1 under the Securities Act of 1933, as amended, filed with and declared effective by the SEC on May 2, 2014.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; and the estimated useful lives of property and equipment.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with a bank which exceeds insured limits, and accounts receivable and unbilled services. The Company performs ongoing credit evaluations of customer’s financial condition and does not require collateral.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.
Accounts Receivable and Unbilled Services	'
	Accounts Receivable and Unbilled Services
	Accounts receivable and unbilled services consist of amounts billed and unbilled under the Company’s service contracts with its customers. The Company extends credit to customers without requiring collateral. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. The allowance for bad debts was $0 and $163 as of June 30, 2014, and December 31, 2013, respectively.
Deferred Financing Costs	'
	Deferred Financing Costs
	Deferred financing costs are transaction costs associated with issuing debt as well as costs related to a deemed contribution for a guarantee from a related party. The Company recognizes these costs in the balance sheet as noncurrent assets. Deferred financing costs are amortized over the life of the related debt.
Deferred Offering Costs	'
	Deferred Offering Costs
	Deferred offering costs are expenses directly related to the IPO. These costs consist of legal, accounting, printing, and filing fees that the Company capitalized, including fees incurred by the independent registered public accounting firm directly related to the offering. The deferred offering costs were offset against the IPO proceeds in May 2014 and were settled to additional paid-in capital.
Revenue Recognition and Deferred Revenue	'
	Revenue Recognition and Deferred Revenue
	The Company derives the majority of its revenue from providing contract research and development services under fee for service arrangements. The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales.
	Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured.
	When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements. If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting.
	An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered.
	The Company’s contract research and development services revenue is recognized in the period in which the services are performed. The Company historically has recognized milestone payments received on a straight-line basis over the remaining service period. No milestone payments were received in the periods presented in the accompanying statements of operations. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. Therefore, license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company recognized an immaterial amount of license revenue from the receipt of upfront payments in the accompanying statement of operations. The Company has not received any royalty payments to date.
	The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement.
	Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets.
	The Company’s deferred revenue comprises upfront payments received and is recognized over the estimated relationship period. The Company received upfront payments of $313, $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue from these upfront payments of $96 and $189 for the three and six months ended June 30, 2014, respectively, and $0 and $62 for the three and six months ended June 30, 2013, respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.
	The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:
		•	Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
		•	Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
		•	Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Research and Development	'
	Research and Development
	Major components of research and development costs include cash compensation, stock-based compensation, preclinical studies, clinical trial and related clinical manufacturing, drug development, materials and supplies, legal, regulatory compliance, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf.
Amortization of Deferred Financing Costs and Debt Discount	'
	Amortization of Deferred Financing Costs and Debt Discount
	Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (Note 4), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party.
Comprehensive Income or Loss	'
	Comprehensive Income or Loss
	The Company has no items of comprehensive income or loss other than net income or loss.
Income Taxes	'
	Income Taxes
	The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service period.
	The Company also accounts for equity instruments issued to non-employees using a fair value approach. The Company values equity instruments and stock options granted to employees using the Black-Scholes valuation model. The measurement of non-employee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received. The Company estimates the fair value of common stock warrants granted to lenders at their intrinsic value, which is the estimated fair value of the common stock less the exercise price for the warrant.
Basic and Diluted Earnings (Net Loss) per Share of Common Stock	'
	Basic and Diluted Earnings (Net Loss) per Share of Common Stock
	The Company uses the two-class method to compute earnings (net loss) per common share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the board of directors that were made to common stockholders, and as a result were considered participating securities.

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consists of the following:
		June 30,		December 31,
		2014		2013
	Equipment	$	9,891	$	9,577
	Furniture and fixtures		378		378
	Leasehold improvements		13,115		13,115
	Total property and equipment		23,384		23,070
	Less accumulated depreciation		18,335		17,669
	Property and equipment, net	$	5,049	$	5,401

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments	'
	Future minimum lease payments for all operating leases as of June 30, 2014 are as follows:
	2014	$	530
	2015		1,075
	2016		1,104
	2017		1,123
	2018		1,156
	Thereafter		291
	Total	$	5,279

Convertible_Preferred_Stock_Ta

Convertible Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Summary of Authorized, Issued and Outstanding Preferred Shares	'
	The following table summarizes authorized, issued and outstanding preferred shares as of May 7, 2014, immediately prior to the automatic conversion to shares of common stock:
		Authorized			Issued and
					Outstanding
	Series A Preferred		31,410			31,407
	Series B Preferred		711,987			467,814
	Series C Preferred		2,967,678			2,770,633
	Series C-1 Preferred		3,076,923			—
	Series C-2 Preferred		2,347,826			2,347,826
	Series D-1 Preferred		10,000,000			6,054,255
	Series D-2 Preferred		10,000,000			6,131,338
	Total		29,135,824			17,803,273
Summary of Preferred Stock Activity	'
	The following table summarizes preferred stock activity for the six months ended June 30, 2014:
		Shares of
		Series A			Series B			Series C			Series C-1		Series C-2			Series D-1			Series D-2
		Convertible			Convertible			Convertible			Convertible		Convertible			Convertible			Convertible
		Preferred			Preferred			Preferred			Preferred		Preferred			Preferred			Preferred
		Stock			Stock			Stock			Stock		Stock			Stock			Stock
	Balance, December 31, 2013		31,407			467,814			2,770,633			—		2,347,826			6,054,255			5,742,697
	Issuance of Series D-2 Preferred		—			—			—			—		—			—			388,641
	Automatic conversion to common stock		(31,407	)		(467,814	)		(2,770,633	)		—		(2,347,826	)		(6,054,255	)		(6,131,338	)
	Balance, June 30, 2014		—			—			—			—		—			—			—

Common_Stock_Tables

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Summary of Common Stock Shares Activity	'
	The following table summarizes common stock share activity for the six months ended June 30, 2014:
			Shares of
			Common Stock
	Balance, December 31, 2013			334,068
	Exercise of stock options			416
	Conversion of preferred stock			1,691,884
	Exercise of common stock warrants			275,687
	Common stock issued through IPO			6,200,000
	Balance, June 30, 2014			8,502,055
Schedule of Reserved Shares of Common Stock for Future Issuance	'
	The Company had reserved shares of common stock for future issuance as follows:
			As of		As of
			June 30,		December 31,
			2014		2013
	For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased			—		1,675,812
	Outstanding stock options *			215,467		137,610
	Outstanding common stock warrants			—		257,242
	For possible future issuance under stock option plan *			228,812		49,734
	For possible future issuance under employee stock purchase plan			47,794		—
	Total common shares reserved for future issuance			492,073		2,120,398
	*	Excludes the effects of the 2014 Equity Incentive Plan amendment and option grants described in Note 8, which were approved by the Board of Directors on June 18, 2014 but are contingent upon approval by the Company’s stockholders.

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation Expense Related to Stock Options	'
	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Cost of revenue	$	37	$	11	$	50	$	22
	Research and development		100		7		162		14
	Selling, general and administrative		135		24		170		47
		$	272	$	42	$	382	$	83

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	'
	The following table summarizes the computation of basic and diluted net income (loss) per share attributable to the Company’s common stockholders:
		Three Months Ended						Six Months Ended
		2014			2013			2014			2013
	Net income (loss)	$	2,233		$	(2,703	)	$	2,645		$	(4,772	)
	Deemed dividend for beneficial conversion feature on Series D-2 Preferred		—			—			(909	)		—
	Deemed dividend for antidilution adjustments to convertible preferred stock		—			—			(214	)		—
	Accretion of convertible preferred stock		—			—			(510	)		—
	Allocation of net income to convertible preferred stockholders		(262	)		—			(303	)		—
	Net income (loss) attributable to common stock - basic	$	1,971		$	(2,703	)	$	709		$	(4,772	)
	Derivative fair value adjustment		(7,297	)		—			(10,080	)		—
	Net loss attributable to common stock - diluted	$	(5,326	)	$	(2,703	)	$	(9,371	)	$	(4,772	)
	Weighted-average common shares outstanding - basic		5,181,174			335,889			2,771,020			335,835
	Allocation of common stock warrants as participating securities		273,197			—			273,709			—
	Weighted-average of outstanding common stock - diluted		5,454,371			335,889			3,044,729			335,835
	Net income (loss) per share
	Basic	$	0.38		$	(8.05	)	$	0.26		$	(14.21	)
	Diluted	$	(0.98	)	$	(8.05	)	$	(3.08	)	$	(14.21	)
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	'
	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because the effect is anti-dilutive. The convertible preferred stock securities will no longer be potentially dilutive in future periods because, as discussed in Note 6, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices.
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Convertible preferred stock:
	Series A Preferred		6,149			6,149			6,149			6,149
	Series B Preferred		131,685			93,566			131,685			93,566
	Series C Preferred		783,515			554,174			783,515			554,174
	Series C-2 Preferred		173,213			119,958			173,213			119,958
	Series D-1 Preferred		296,773			—			296,773			—
	Series D-2 Preferred		300,549			—			300,549			—
	Warrants to purchase Series C-1 Preferred		14,033			9,846			14,033			9,846
	Warrants to purchase common stock		—			114,987			—			114,987
	Stock options		215,467			—			215,467			—
	Convertible notes		—			475,323			—			475,323

RelatedParty_Transactions_Tabl

Related-Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Summary of Transactions with Related Parties	'
	The Company had transactions with related parties as follows:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Revenue	$	1,822	$	1,822	$	3,644	$	3,644
	Selling, general and administrative expense		500		—		500		—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis	'
	The following table summarizes the conclusions reached as of December 31, 2013:
		Balance as of			Quoted Prices in		Significant Other		Significant
		December 31, 2013			Active Markets for		Observable Inputs		Unobservable
					Identical Assets		(Level 2)		Inputs
					(Level 1)				(Level 3)
	Derivative liability — Series C-1 warrants	$	37		$	—	$	—	$	37
	Derivative liability — common stock warrants		12,200			—		—		12,200
	Total derivative liability	$	12,237		$	—	$	—	$	12,237
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	'
	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:
		Six months ended
		June 30, 2014
	Beginning balance, December 31, 2013	$	12,237
	Issuance of warrants		544
	Excess of fair value of warrants over proceeds		362
	Adjustment to fair value		(10,442	)
	Reclassification to additional paid-in capital upon exercise of warrants		(2,701	)
	Ending balance, June 30, 2014	$	—

Description_of_Business_and_Ba1

Description of Business and Basis of Preparation - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended	6 Months Ended
In Thousands, except Share data, unless otherwise specified	7-May-14	Apr. 25, 2014	Mar. 17, 2014	31-May-14	Jun. 30, 2014	Jun. 30, 2013	7-May-14	Mar. 13, 2014
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]	'	'	'	'	'	'	'	'
Formation date	'	'	'	'	4-Nov-99	'	'	'
Reverse stock split ratio, description	'	'	'	'	'1-for-4 reverse stock split	'	'	'
Reverse stock split ratio	'	0.196	0.25	'	'	'	'	'
Number of shares of common stock sold	6,200,000	'	'	'	6,200,000	'	'	'
Public offering price per share	'	'	'	'	'	'	$10	'
Net proceeds from initial public offering (IPO)	$54,583	'	'	'	'	'	'	'
Underwriting discounts and commissions	3,290	'	'	'	'	'	'	'
Offering expenses	4,127	'	'	'	'	'	'	'
Number of outstanding shares of convertible preferred stock converted into common stock	'	'	'	'	'	'	1,691,884	1,691,884
Outstanding warrants exercised	275,687	'	'	275,687	275,687	'	'	'
Outstanding debt paid in full upon completion of the IPO	'	'	'	'	15,000	0	'	'
Additional Reverse Stock Split [Member]	'	'	'	'	'	'	'	'
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]	'	'	'	'	'	'	'	'
Reverse stock split ratio, description	'	'	'	'	'1-for-5.1 reverse stock split	'	'	'
2013 Credit Agreement [Member]	'	'	'	'	'	'	'	'
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]	'	'	'	'	'	'	'	'
Outstanding debt paid in full upon completion of the IPO	$15,000	'	'	'	'	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended			3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'
Allowance for bad debts	'	'	'	$0	'	$0	'	$163
Milestone payments received	'	'	'	'	'	0	'	'
Royalty payments received	'	'	'	'	'	0	'	'
Upfront payment received	500	1,500	313	'	'	'	'	'
Deferred revenue recognition period	'48 months	'70 months	'6 months	'	'	'	'	'
Revenue recognized from upfront payments	'	'	'	$96	$0	$189	$62	'

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$23,384	$23,070
Less accumulated depreciation	18,335	17,669
Property and equipment, net	5,049	5,401
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	9,891	9,577
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	378	378
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$13,115	$13,115

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Plant And Equipment [Abstract]	'	'	'	'
Depreciation expense	$307	$343	$615	$691
Proceeds from insurance recovery	$165	$0	$165	$0

Debt_Obligations_Additional_In

Debt Obligations - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

31-May-14

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2011

Apr. 30, 2010

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

7-May-14

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 11, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 11, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 11, 2013

Jun. 30, 2013

Jun. 30, 2014

Dec. 11, 2013

Dec. 31, 2013

Dec. 11, 2013

Dec. 11, 2013

Dec. 11, 2013

Dec. 11, 2013

Dec. 11, 2013

Dec. 31, 2013

Dec. 11, 2013

Dec. 11, 2013

Dec. 31, 2011

Jun. 30, 2014

Apr. 30, 2010

Dec. 31, 2013

Apr. 30, 2010

Dec. 31, 2013

2010 Credit Agreement [Member]

2010 Credit Agreement [Member]

2010 Credit Agreement [Member]

2010 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

2013 Credit Agreement [Member]

December 2011 Note and Warrant Agreement [Member]

December 2011 Note and Warrant Agreement [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

June 2013 Note and Warrant Agreement [Member]

June 2013 Note and Warrant Agreement [Member]

June 2013 Note and Warrant Agreement [Member]

June 2013 Note and Warrant Agreement [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Investor [Member]

Two Thousand Thirteen Credit Facility [Member]

Term Loan [Member]

Term Loan [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

June 2013 Note and Warrant Agreement [Member]

June 2013 Note and Warrant Agreement [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2011-2012 Notes [Member]

2010 Credit Agreement [Member]

2013 Credit Agreement [Member]

2010 Credit Agreement [Member]

2013 Credit Agreement [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility agreement amount

'

'

'

'

'

'

'

'

$15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

$5,000,000

$10,000,000

$10,000,000

Interest at a rate of London InterBank plus

'

'

'

'

'

'

'

'

0.95%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed contribution of a loan guarantee

'

'

0

3,930,000

'

'

'

'

6,338,000

'

'

'

'

'

'

'

3,930,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized deferred financing costs

'

'

'

'

'

'

'

'

'

'

'

153,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan repayment from proceeds from planned IPO

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

Aggregate borrowing reduction under Credit Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

Repayment date of Credit Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-14

'

'

'

'

Outstanding debt plus accrued interest

'

'

15,000,000

0

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

-1,389,000

0

-1,389,000

0

'

'

'

'

'

'

'

'

'

1,389,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Outstanding

0

'

0

'

'

'

15,000,000

'

'

'

'

'

'

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of deferred financing costs

219,000

813,000

755,000

1,522,000

'

'

'

'

'

219,000

755,000

'

'

'

534,000

'

1,243,000

'

'

'

0

10,000

0

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

1.19%

1.23%

1.19%

1.22%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

5,000

46,000

49,000

96,000

'

'

'

'

'

'

'

'

'

5,000

46,000

49,000

96,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt agreement, maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes aggregate amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

899,000

'

'

'

'

'

'

'

'

'

'

'

11,444,000

'

'

'

'

'

Number of warrants issued to purchase common stock

'

'

'

'

'

19,048

'

26,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,532

'

'

'

'

'

'

'

26,000

'

'

'

'

'

Exercise price of warrants

'

'

'

'

0.2

0.2

'

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.2

'

'

'

'

'

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes stated interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Required percentage written consent by holders of outstanding aggregated principle amount of convertible notes

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of issued warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

328,000

'

'

'

'

'

'

'

'

'

'

1,168,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of issued warrants above the face value of the Notes expensed at issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

269,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining amount of the fair value of issued warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

899,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,444,000

'

'

'

'

'

899,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,640,000

'

'

'

'

'

'

'

$33,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares converted to preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,956,985

'

3,291,443

'

665,542

'

6,054,255

6,054,255

'

'

'

'

'

'

'

Convertible preferred stock conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.40

'

$1.40

'

'

$1.40

'

'

'

'

'

'

Conversion price adjusted per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.40

'

'

'

'

'

$1.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
	Agreement		Agreement		Clinical Development Arrangement [Member]	Clinical Development Arrangement [Member]
Commitment And Contingencies [Line Items]	'	'	'	'	'	'
Lease expiration	'	'	'2019	'	'	'
Lease expiration extension	'	'	31-Mar-24	'	'	'
Rent expense	$236,000	$227,000	$467,000	$450,000	'	'
Milestone payments from the Company	'	'	19,000,000	'	'	'
Number of additional license agreements	2	'	2	'	'	'
License agreements fee	2,300,000	'	2,300,000	'	'	'
Projected fees and expenses under agreement	'	'	'	'	$6,200,000	$0
Agreement termination period	'	'	'	'	'30 days	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014	$530
2015	1,075
2016	1,104
2017	1,123
2018	1,156
Thereafter	291
Total	$5,279

Convertible_Preferred_Stock_Ad

Convertible Preferred Stock - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Mar. 13, 2014

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

31-May-14

7-May-14

Mar. 13, 2014

Jan. 31, 2014

Dec. 31, 2011

Dec. 31, 2000

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2000

Dec. 31, 2000

Dec. 31, 2000

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Dec. 31, 2012

Jan. 31, 2005

Dec. 31, 2002

Dec. 31, 2001

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Dec. 31, 2012

Jul. 31, 2006

Aug. 31, 2004

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 31, 2014

Dec. 11, 2013

Mar. 31, 2008

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 11, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-1 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series C-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-2 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Series D-1 Convertible Preferred Stock [Member]

Investor

Temporary Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

'

'

'

'

'

'

$0.00

$0.00

$0.00

'

'

'

$0.00

'

$0.00

'

'

'

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

$0.00

'

'

'

'

$0.00

'

$0.00

'

'

'

$0.00

$0.00

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

0

31,407

31,407

'

600,999

0

'

467,814

'

'

'

2,867,154

'

0

'

2,770,633

'

'

'

984,615

'

'

'

'

'

'

2,347,826

0

'

2,347,826

'

'

'

'

0

388,641

5,742,697

1,785,712

'

'

0

6,054,255

Issue Price

'

'

'

'

'

'

'

'

'

'

'

'

$7.96

'

$9.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.40

'

$1.40

'

'

'

'

Consideration in the form of equipment, intellectual property, and conversion of existing debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration in cash

'

544

544

0

'

'

'

'

'

'

'

'

'

'

3,215

'

'

'

'

'

'

24,000

'

'

'

'

'

'

'

3,200

'

'

'

'

'

'

13,500

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

'

Issuance costs

'

'

'

'

'

'

'

'

'

'

'

'

'

43

'

'

'

'

'

'

'

86

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

95

'

'

'

'

'

'

'

'

Preferred stock, additional shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

244,173

'

'

'

'

'

'

'

197,045

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued to purchase common stock

'

'

'

'

'

'

'

19,048

26,000

'

'

'

'

'

'

'

'

'

'

'

'

'

100,524

'

'

'

'

'

196,923

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,532

'

'

'

'

Exercise price of warrants

'

'

'

'

0.2

'

'

0.2

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

'

'

'

'

'

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.2

'

'

'

'

Number of investors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration in mode of convertible notes and accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,513

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on convertible notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued upon exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants, debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

459

'

'

'

'

'

'

'

'

'

'

'

'

906

'

4,214

'

'

'

'

'

'

'

'

Adjustment to fair value

'

'

-10,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

37

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Jul-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32.29

'

$45.95

'

'

'

'

'

$36.24

'

$51.77

'

'

'

'

'

'

'

$46.11

$66.30

'

'

$78.96

'

$117

'

'

'

'

'

'

$28.56

$1.40

'

$1.40

'

Conversion price, reduced due to anti-dilution provisions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32.01

'

$32.29

'

'

'

'

'

$35.89

'

$36.24

'

'

'

'

'

'

'

$45.61

$46.11

'

'

$77.94

'

$78.96

'

'

'

'

'

'

'

'

'

'

'

Excess of fair value of warrants over proceeds

'

362

362

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

362

'

1,714

'

'

'

'

'

'

'

'

Fair value of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$47.74

'

$48.35

'

'

'

'

Intrinsic value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,232

'

'

'

'

'

'

'

'

Effective conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

Shares converted to preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,956,985

'

'

'

'

'

'

6,054,255

'

'

Public offering gross proceeds threshold required to trigger provisions for automatic conversion of preferred stock

$20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock into common stock

'

'

'

'

'

1,691,884

1,691,884

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible_Preferred_Stock_Su

Convertible Preferred Stock - Summary of Authorized, Issued and Outstanding Preferred Shares (Detail)	Jun. 30, 2014	7-May-14	Dec. 31, 2013
Temporary Equity [Line Items]	'	'	'
Authorized	'	29,135,824	'
Issued and Outstanding	'	17,803,273	'
Series A Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	31,410	31,410
Issued and Outstanding	'	31,407	'
Series B Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	711,987	711,987
Issued and Outstanding	'	467,814	'
Series C Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	2,967,678	2,967,678
Issued and Outstanding	'	2,770,633	'
Series C-1 Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	'	3,076,923	'
Issued and Outstanding	'	0	'
Series C-2 Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	2,347,826	2,347,826
Issued and Outstanding	'	2,347,826	'
Series D-1 Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	10,000,000	10,000,000
Issued and Outstanding	'	6,054,255	'
Series D-2 Convertible Preferred Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Authorized	0	10,000,000	10,000,000
Issued and Outstanding	'	6,131,338	'

Convertible_Preferred_Stock_Su1

Convertible Preferred Stock - Summary of Preferred Stock Activity (Detail)	6 Months Ended
	Jun. 30, 2014
Series A Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	31,407
Issuance of Temporary Equity	0
Automatic conversion to common stock	-31,407
Ending balance	0
Series B Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	467,814
Issuance of Temporary Equity	0
Automatic conversion to common stock	-467,814
Ending balance	0
Series C Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	2,770,633
Issuance of Temporary Equity	0
Automatic conversion to common stock	-2,770,633
Ending balance	0
Series C-1 Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	0
Issuance of Temporary Equity	0
Automatic conversion to common stock	0
Ending balance	0
Series C-2 Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	2,347,826
Issuance of Temporary Equity	0
Automatic conversion to common stock	-2,347,826
Ending balance	0
Series D-1 Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	6,054,255
Issuance of Temporary Equity	0
Automatic conversion to common stock	-6,054,255
Ending balance	0
Series D-2 Convertible Preferred Stock [Member]	'
Temporary Equity [Line Items]	'
Beginning balance	5,742,697
Issuance of Temporary Equity	388,641
Automatic conversion to common stock	-6,131,338
Ending balance	0

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

7-May-14

Jan. 31, 2014

31-May-14

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

7-May-14

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2011

Dec. 11, 2013

Dec. 11, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 11, 2013

Dec. 11, 2013

Series D-2 Purchase Agreement [Member]

Series D-2 Purchase Agreement [Member]

Common Stock Warrants [Member]

Common Stock Warrants [Member]

Common Stock Warrants [Member]

Common Stock Warrants [Member]

June 2013 Note and Warrant Agreement [Member]

June 2013 Note and Warrant Agreement [Member]

Schedule of Capitalization, Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

'

'

$0.00

'

$0.00

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

125,000,000

'

125,000,000

'

'

'

70,000,000

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

'

'

8,502,055

'

8,502,055

'

'

'

334,068

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

'

'

'

8,502,055

'

8,502,055

'

'

'

334,068

'

'

'

'

'

'

'

'

'

Number of warrants issued to purchase common stock

'

'

'

'

'

'

'

'

19,048

'

26,000

'

87,532

'

'

'

'

'

88,987

Exercise price of warrants

'

'

0.2

'

'

'

'

'

0.2

'

0.2

'

0.2

'

'

'

'

'

0.2

Expiration date of warrants

'

'

'

'

'

30-Jun-17

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable date

'

'

'

'

'

'

'

'

'

'

'

11-Dec-18

'

'

'

'

'

28-Jun-18

'

Increase in the shares of common stock underlying the warrants issued

'

'

'

'

'

'

'

'

'

'

'

54,120

'

'

'

'

'

'

'

Revised number of common shares underlying the warrants issued

'

'

'

'

'

'

'

'

'

'

'

80,120

'

'

'

'

'

'

'

Exercise of common stock warrants

275,687

'

275,687

'

'

275,687

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of common stock warrant derivative liabilities

'

'

'

$0

'

$0

'

$2,701

'

$12,237

'

'

'

'

'

'

'

'

'

Other (expense) income related to fair value adjustment of long term derivative liability

'

'

'

'

'

-10,442

'

'

'

'

'

'

'

7,297

0

10,442

0

'

'

Excess of fair value of warrants over proceeds

'

362

'

'

'

362

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative fair value adjustment

'

'

'

$7,297

$0

$10,080

$0

'

'

'

'

'

'

'

'

'

'

'

'

Common_Stock_Summary_of_Common

Common Stock - Summary of Common Stock Shares Activity (Detail)	0 Months Ended	1 Months Ended	6 Months Ended
	7-May-14	31-May-14	Jun. 30, 2014
Equity [Abstract]	'	'	'
Balance, December 31, 2013	'	'	334,068
Exercise of stock options	'	'	416
Conversion of preferred stock	'	'	1,691,884
Exercise of common stock warrants	275,687	275,687	275,687
Common stock issued through IPO	6,200,000	'	6,200,000
Balance, June 30, 2014	'	'	8,502,055

Common_Stock_Schedule_of_Reser

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)	Jun. 30, 2014	Dec. 31, 2013
Equity [Abstract]	'	'
For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased	0	1,675,812
Outstanding stock options	215,467	137,610
Outstanding common stock warrants	0	257,242
For possible future issuance under stock option plan	228,812	49,734
For possible future issuance under employee stock purchase plan	47,794	0
Total common shares reserved for future issuance	492,073	2,120,398

Stockbased_Compensation_Additi

Stock-based Compensation - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 18, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 18, 2014

Jun. 18, 2014

Apr. 29, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 18, 2014

2-May-14

Apr. 29, 2014

Jun. 18, 2014

Jun. 18, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 18, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2009 Stock Option Plan [Member]

2014 Equity Incentive Plan [Member]

2014 Equity Incentive Plan [Member]

2014 Equity Incentive Plan [Member]

1999 Stock Option Plan [Member]

2014 Employee Stock Purchase Plan [Member]

2014 Employee Stock Purchase Plan [Member]

Pre Modification [Member]

Post Modification [Member]

Scenario, Previously Reported [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

110.00%

'

'

'

'

'

'

Vesting period of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

'

'

Expiration period of options

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective date of equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2-May-14

'

'

'

'

Number of additional awards expected to be granted

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Base number of new shares available for future issuance under equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

257,352

'

'

'

Equity incentive plan, activity of share reserve, description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The share reserve will automatically increase on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year

'

'

'

'

Common stock issuable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Common stock outstanding percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

'

'

0.80%

'

Number of shares of common stock for future issuance, board of directors prerogative, increase in period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

0

'

Aggregate number of shares of the Company's common stock that may be issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

351,653

'

'

'

'

'

Grant of options to purchase shares of common stock, subject to stockholder approval

396,573

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Modified exercise price, subject to stockholder approval

'

'

'

'

'

'

$9.64

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation cost

$0

$272

$42

$382

$83

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock available for future issuance

'

228,812

'

228,812

'

49,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,812

'

'

'

'

2009 Stock Option Plan, Plan Modification, Description and Terms

'

'

'

'During the quarter ended June 30, 2014, the Board of Directors of the Company approved the following with respect to the 2009 Stock Option Plan: On April 29, 2014, the exercise price per share of certain options to purchase 53,404 shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $10.00 per share, the initial public offering price per share in the IPO. The original exercise prices of such options ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $54.87 per share. On June 18, 2014, the exercise price per share of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $9.64 per share, the closing stock price on June 18, 2014. This modification lowered the exercise price of outstanding options to purchase 110,346 shares of common stock, including those options to purchase common stock that were previously modified on April 29, 2014. These outstanding stock options had exercise prices that ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $41.87 per share. Also on June 18, 2014, the contractual term of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was extended to June 17, 2024.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options to purchase shares of common stock, for which the exercise price was lowered to the IPO price

'

'

'

'

'

'

'

'

'

'

'

110,346

'

53,404

'

'

'

'

'

'

'

'

'

'

'

Modified exercise price

'

'

'

'

'

'

'

'

'

'

'

$9.64

'

$10

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options, lower range

'

'

'

'

'

'

'

$20.40

$20.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options, upper range

'

'

'

'

'

'

'

$61.20

$61.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price of outstanding options

'

'

'

'

'

'

'

'

'

'

'

$41.87

'

$54.87

$3.08

$5.87

'

'

'

'

'

'

'

'

'

Additional compensation cost

'

'

'

'

'

'

'

'

'

293

'

'

'

'

'

'

130

'

'

'

'

'

0

'

'

Effective date of employee stock purchase plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2-May-14

'

Number of shares of common stock issuable

'

47,794

'

47,794

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,794

Common stock issuable description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock

'

Common stock issuable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Employee stock purchase plan, number of shares, which might be added to common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,411

'

Total income tax benefit recognized

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash received from option exercised

'

$4

'

$9

$3

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockbased_Compensation_Stockb

Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 18, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense related to stock options	$0	$272	$42	$382	$83
Cost of Revenue [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense related to stock options	'	37	11	50	22
Research and Development [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense related to stock options	'	100	7	162	14
Selling, General and Administrative [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock-based compensation expense related to stock options	'	$135	$24	$170	$47

Earnings_Per_Share_Summary_of_

Earnings Per Share - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income (loss)	$2,233	($2,703)	$2,645	($4,772)
Deemed dividend for beneficial conversion feature on Series D-2 Preferred	0	0	-909	0
Deemed dividend for antidilution adjustments to convertible preferred stock	0	0	-214	0
Accretion of convertible preferred stock	0	0	-510	0
Allocation of net income to convertible preferred stockholders	-262	0	-303	0
Net income (loss) attributable to common stock - basic	1,971	-2,703	709	-4,772
Derivative fair value adjustment	-7,297	0	-10,080	0
Net loss attributable to common stock - diluted	($5,326)	($2,703)	($9,371)	($4,772)
Weighted-average common shares outstanding - basic	5,181,174	335,889	2,771,020	335,835
Allocation of common stock warrants as participating securities	273,197	0	273,709	0
Weighted-average of outstanding common stock - diluted	5,454,371	335,889	3,044,729	335,835
Basic	$0.38	($8.05)	$0.26	($14.21)
Diluted	($0.98)	($8.05)	($3.08)	($14.21)

Earnings_Per_Share_Summary_of_1

Earnings Per Share - Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Series A Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	6,149	6,149	6,149	6,149
Series B Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	131,685	93,566	131,685	93,566
Series C Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	783,515	554,174	783,515	554,174
Series C-2 Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	173,213	119,958	173,213	119,958
Series D-1 Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	296,773	0	296,773	0
Series D-2 Convertible Preferred Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	300,549	0	300,549	0
Warrant [Member] | Common Stock [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	0	114,987	0	114,987
Warrant [Member] | Series C-1 Preferred [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	14,033	9,846	14,033	9,846
Stock Options [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	215,467	0	215,467	0
Convertible Notes [Member]	'	'	'	'
Convertible preferred stock:	'	'	'	'
Anti-Dilutive Securities	0	475,323	0	475,323

RelatedParty_Transaction_Summa

Related-Party Transaction - Summary of Transactions with Related Parties (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Related Party Transactions [Abstract]	'	'	'	'
Revenue	$1,822	$1,822	$3,644	$3,644
Selling, general and administrative expense	$500	'	$500	'

RelatedParty_Transactions_Addi

Related-Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended		1 Months Ended		3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	31-May-14	31-May-13	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Sanofi [Member]	Burrill Securities [Member]	Burrill Securities [Member]	Sales [Member]	Sales [Member]	Sales [Member]	Sales [Member]
						Sanofi [Member]	Sanofi [Member]	Sanofi [Member]	Sanofi [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Ownership percentage of a related party in a customer of the company	'	'	100.00%	'	'	'	'	'	'
Percentage of related-party revenue	'	'	'	'	'	39.00%	43.00%	39.00%	40.00%
Percentage of professional fees	'	'	'	'	5.00%	'	'	'	'
General and administrative expense	$500	$500	'	$500	'	'	'	'	'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Jun. 30, 2014	7-May-14	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary Of Derivative Instruments [Abstract]	'	'	'
Fair value of assets and liablilities on a recurring basis	$0	$2,701	$12,237

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	7-May-14	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	$0	$2,701	$12,237
Fair Value, Measurements, Recurring [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	12,237
Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	37
Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	12,200
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	0
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	12,237
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	37
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrants [Member]	'	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'	'
Derivative liability	'	'	$12,200

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	0 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net [Abstract]	'	'	'
Beginning balance	'	$12,237	'
Issuance of warrants	'	544	'
Excess of fair value of warrants over proceeds	362	362	'
Adjustment to fair value	'	-10,442	'
Reclassification to additional paid-in capital upon exercise of warrants	'	-2,701	0
Ending balance	'	$0	'

Significant_Agreements_Additio

Significant Agreements - Additional Information (Detail) (USD $)	1 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				R-Pharm CJSC [Member]	Elanco Animal Health [Member]	Elanco Animal Health [Member]	Elanco Animal Health [Member]	Elanco Animal Health [Member]	Elanco Animal Health [Member]
						First Two Years [Member]	Second Two Years [Member]	U.S. [Member]	European Union [Member]
Significant Agreements [Line Items]	'	'	'	'	'	'	'	'	'
Upfront payment received	$500	$1,500	$313	$1,500	'	'	'	'	'
Development milestone payment	'	'	'	3,000	1,500	'	'	'	'
Sales-based payments	'	'	'	15,000	'	'	'	'	'
Deferred revenue recognition period	'48 months	'70 months	'6 months	'70 months	'	'	'	'	'
Fees for multi-year contract research and development services	'	'	'	'	'	2,750	3,000	'	'
Payment for first US regulatory approval	'	'	'	'	'	'	'	2,000	'
Payment for first commercial sale of product	'	'	'	'	'	'	'	4,000	1,500
Payment for reaching specified annual sales	'	'	'	'	$15,000	'	'	'	'

Severance_Costs_Additional_Inf

Severance Costs - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
Restructuring And Related Activities [Abstract]	'	'
Severance costs	$379	$379